Skip to main content
. Author manuscript; available in PMC: 2018 Apr 30.
Published in final edited form as: Sci Signal. 2017 Oct 31;10(503):eaan1011. doi: 10.1126/scisignal.aan1011

Figure 3. RXRA in GCSF-induced granulopoiesis and hematopoietic stem cell mobilization.

Figure 3

(A) White blood cell (WBC) count of C57BL6 mice treated with or without GCSF and bexarotene as indicated. (B) Neutrophil (NE) count of C57BL6 mice treated with or without GCSF and bexarotene as indicated. (C) Absolute number of Kit+Lin-Sca-1+ (KLS) cells in 10 μl peripheral blood of C57BL6 mice treated with or without GCSF and bexarotene as indicated. (D) Absolute number of Kit+Lin-Sca-1- (progenitors) cells in 10 μl peripheral blood of C57BL6 mice treated with or without GCSF and bexarotene as indicated. (E) Colony forming units in 10 μl peripheral blood of C57BL6 mice treated with or without GCSF and bexarotene as indicated. (F) WBC count of Rxraflox/flox × Rxrbflox/flox × Mx1-Cre (RXR-KO) mice and Rxraflox/flox × Rxrbflox/flox (RXR-WT) mice treated with GCSF. (G) NE count of RXR-KO mice and RXR-WT mice treated with GCSF. (H) Colony number generated from 10 μl peripheral blood of RXR-KO mice and RXR-WT mice. (I) Absolute number of Kit+Lin-Sca-1+ (KLS) cells and Kit+Lin-Sca-1- (progenitors) cells in 10 μl peripheral blood of RXR-KO mice and RXR-WT mice. A – B, control mice, N = 16; GCSF treated mice, N = 20; GCSF + bexarotene, N = 19 mice. C – E, control mice, N = 11; GCSF treated mice, N = 15; GCSF + bexarotene treated mice, N = 15. F – I, RXR-KO mice, n = 3; WT mice, n = 4. Error bars represent standard deviation between individual mice. * P < 0.05, ** P < 0.01, *** P < 0.001, ANOVA with Tukey’s multiple comparison test.